Abstract 5710
Background
Merkel cell carcinoma (MCC) is a rare, aggressive tumour of the skin associated with high recurrence rates and poor survival. Clinical trials have shown activity of various checkpoint inhibitors targeting programmed death-(ligand)-1 (PD-(L)1). Avelumab is currently the only PD-L1 inhibitor that has been approved in the Netherlands for advanced/metastatic MCC (mMCC). Here, we report the Dutch real-world efficacy data of avelumab in patients with mMCC.
Methods
All mMCC patients from 4 tertiary referral centres in the Netherlands from December 2016 were analysed. Patients were included in this analysis if they had received avelumab for mMCC, regardless of other previous lines of therapy. Patient data were collected retrospectively and followed up prospectively after initiation of data collection. Primary endpoints were response rate (RR) and duration of response (DOR) , secondary endpoints were progression free survival (PFS), overall survival (OS) and toxicity. Toxicity was evaluated according to CTCAE version 5.0.
Results
Forty-six patients received avelumab, of which 37 patients were evaluable for response (9 had not reached response evaluation, 1 died due to comorbidity). In 22 (59.5%) patients avelumab was first-line treatment. Median follow up time was 7.8 (IQR 3.7-10.1) months. RR was 59.5% (n = 22) with 21.6% (n = 8) of patients having a complete radiological response. Median DOR was 6.3 (IQR 3.0-12.5) months and 15 (40.5%) patients had ongoing response at time of data analysis. Median PFS was 12.2 (95% CI 3.3-21.1) months, median OS was not yet reached. In subgroup analysis no differences were found for the presence of visceral metastases at baseline or previous lines of therapy. Five (13.2%) patients experienced grade 3 toxicity, of which 2 (4.3%) patients discontinued avelumab. No grade 4-5 toxicity were seen.
Conclusions
In the Netherlands treatment with avelumab is increasingly used in first- and second-line treatment for mMCC. In this real-world cohort, RR, DOR, PFS and toxicity results were in line with results from clinical trials and show relatively high, durable responses in patients with mMCC, unaffected by the presence of visceral metastases or previous lines of therapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5383 - A pilot trial to investigate the impact of a personalised self-management lifestyle programme using mobile technology on the health and wellbeing of cancer survivors
Presenter: Mary Grace Kelly
Session: Poster Display session 3
Resources:
Abstract
5084 - The BRIGHTLIGHT national survey of the impact of specialist teenage and young adult cancer care on caregivers’ information and support needs
Presenter: Rachel Taylor
Session: Poster Display session 3
Resources:
Abstract
4328 - Life beyond cancer: Occupational health care service support in returning work experienced by cancer survivals
Presenter: Minna Nurmi
Session: Poster Display session 3
Resources:
Abstract
3337 - Investigating the factors related to primary caregivers' burden in oncology patients in Greece
Presenter: Ourania Govina
Session: Poster Display session 3
Resources:
Abstract
3387 - Factors Influencing the Level of Emotional Support from Nurses Perceived by Patients Undergoing Haematopoietic Stem Cell Transplantation in Protective Isolation
Presenter: Michela Piredda
Session: Poster Display session 3
Resources:
Abstract
935 - Progressive Muscle Relaxation and Guided Imagery Techniques and the Way of Coping of Parents of Children with Malignancies: A randomized controlled trial
Presenter: Tsitsi Theologia
Session: Poster Display session 3
Resources:
Abstract
3457 - Pharmacist and Nurse Led Melanoma Immunotherapy Clinic
Presenter: Dharmisha Chauhan
Session: Poster Display session 3
Resources:
Abstract
5160 - Measuring the impact of the Irish Cancer Society's Cancer Information Services
Presenter: Aileen McHale
Session: Poster Display session 3
Resources:
Abstract
4297 - It's Great to Talk
Presenter: Noreen Andersen
Session: Poster Display session 3
Resources:
Abstract
4444 - Impact of Burn-Out Syndrome in Oncology personnel and its improvement through specific interventions
Presenter: Inmaculada Ortega
Session: Poster Display session 3
Resources:
Abstract